Trials / Completed
CompletedNCT02254018
Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
An Open Phase I Single Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck With Repeated Administration in Patients With Clinical Benefit
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bivatuzumab mertansine |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2005-02-01
- First posted
- 2014-10-01
- Last updated
- 2023-10-24
Source: ClinicalTrials.gov record NCT02254018. Inclusion in this directory is not an endorsement.